Sequencing Company PacBio Cuts Costs Amid Uncertainty Around NIH Funding And New Tariffs

Pacific Biosciences of California Inc. (NASDAQ:PACB) on Wednesday announced preliminary revenue of $36.9 million versus a consensus of $33.49 million.

The company said the first quarter met expectations, despite impacts from ongoing uncertainty in NIH funding in the United States and broader economic headwinds affecting the industry.

Vega system orders accelerated in the first quarter compared to the fourth quarter of 2024. The combination of system capability and its attractive price point enabled purchases from new and existing customers.

The sequencing solutions company said preliminary consumable revenue reached a company record. Annualized Revio pull-through per system was approximately $236,000. That’s in line with the company’s expectations in the low to mid $200,000s range.

Also Read: Enphase Rolls Out Scalable, Grid-Ready IQ Battery 5P in Poland With 15-Year Warranty

“…The Vega launch ...

https://www.benzinga.com/general/health-care/25/04/44719397/sequencing-company-pacbio-cuts-costs-amid-uncertainty-around-nih-funding-and-new-tariffs